REPLIMUNE GROUP, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
REPLIMUNE GROUP, INC. (REPL) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price of $14.99 per share as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice · last filed 2026-08-14
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $14.99.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $16.01.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $16.09.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $16.05.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2026-06-30 | $14.99 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $16.01 10-K · filed 2026-06-29 | |
| 2025-12-31 | $16.09 10-Q · filed 2026-02-03 | |
| 2025-09-30 | $16.05 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $16.17 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $16.82 10-K · filed 2025-05-22 | |
| 2024-12-31 | $16.73 10-Q · filed 2025-02-12 | |
| 2024-09-30 | $16.46 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $16.16 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $15.65 10-K · filed 2024-05-16 | |
| 2023-12-31 | $15.46 10-Q · filed 2024-02-08 | |
| 2023-09-30 | $15.28 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $15.03 10-Q · filed 2023-08-03 | |
| 2022-12-31 | $14.07 10-Q · filed 2023-02-09 | |
| 2022-09-30 | $13.50 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $13.15 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $14.43 10-K · filed 2023-05-18 | $10.85 10-K · filed 2022-05-19 |
| 2021-12-31 | $9.96 10-Q · filed 2022-02-03 | |
| 2021-09-30 | $9.54 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $8.97 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $8.38 10-K · filed 2022-05-19 | |
| 2020-12-31 | $7.82 10-Q · filed 2021-02-04 | |
| 2020-09-30 | $12.82 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $7.01 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $5.67 10-K · filed 2021-05-20 | $5.66 10-K · filed 2020-06-03 |
| 2019-12-31 | $5.33 10-Q · filed 2020-02-13 | |
| 2019-09-30 | $4.90 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $2.54 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $2.51 10-K · filed 2020-06-03 | |
| 2018-12-31 | $2.45 10-Q · filed 2019-02-14 | |
| 2018-09-30 | $2.35 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $1.81 10-Q · filed 2018-08-30 | |
| 2018-03-31 | $1.84 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |